Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.
37 papers
This randomized, double-blind phase 3 trial tested MDMA-assisted therapy versus placebo with the same therapy in 90 adults with severe PTSD. Participants had three drug sessions plus preparatory and integration therapy, and were assessed 18 weeks after starting. The MDMA group had larger drops in PTSD symptoms and in functional…
Researchers tested a nasal spray form of esketamine together with a newly started oral antidepressant in adults whose depression had not improved after trying at least two antidepressants. Over four weeks, people who got esketamine plus a new antidepressant had faster and larger drops in depression symptoms than those who…
A group of international mood-disorder experts reviewed the research on ketamine and esketamine for adults whose depression did not get better with usual antidepressants. They found that these drugs work differently from standard antidepressants and can lift symptoms more quickly for some people with treatment-resistant depression. However, the experts also…
Psychedelic "bad trips" can be intense and sometimes last past the session. Surveys and studies report that a minority of users have serious short- or long-term problems, while other people later say the experience was meaningful or helpful. Risk and duration vary by dose, setting, and support, and studies give…
Ketamine, an anaesthetic, can reduce chronic pain, especially pain with nerve damage. Low doses give strong pain relief, probably by blocking NMDA receptors. Short infusions tend to help only while the drug is given, but three studies found that longer infusions (4–14 days) produced pain relief lasting up to 3…
In a small, double-blind, placebo-controlled trial of Japanese adults aged 50–80 with mild cognitive impairment, 30 people were randomly assigned to take Yamabushitake (an edible mushroom) or placebo for 16 weeks. The mushroom group took four 250 mg tablets three times a day and showed higher scores on a cognitive…
Researchers pooled results from 205 intravenous ketamine infusions (0.5 mg/kg given over 40 minutes) in 97 people with treatment-resistant major depression. About two thirds (67%, 65 of 97) showed a strong antidepressant response (≥50% improvement). Most side effects happened in the first 4 hours and were short-lived. Few infusions were…
This small pilot randomized placebo‑controlled trial tested a cannabinoid spray (Sativex) in 30 adults with ADHD. The main test of cognition and activity (QbTest) showed no significant difference between Sativex and placebo in the intention‑to‑treat analysis (Estimate = -0.17, 95% CI -0.40 to 0.07, p = 0.16). Some secondary measures…
Researchers reviewed studies of drugs that act on serotonin (so-called serotonergic psychedelics) and MDMA. They found that harms and bad reactions are not clearly defined in these studies and are probably reported less often than they actually happen. Some intense or frightening experiences during treatment might help people heal, but…
This study demonstrated that treatment with three infusions of ketamine was well tolerated in patients with alcohol use disorder and was associated with more days of abstinence from alcohol at 6-month follow-up. The findings suggest a possible beneficial effect of adding psychological therapy alongside ketamine treatment.
This was a small, phase 1 open-label study of 10 adult females with anorexia nervosa or partial remission who each received a single 25 mg dose of synthetic psilocybin plus psychological support. The main goal was to check safety and whether the treatment was tolerable and feasible. No serious adverse…
This was a single-blinded, randomized trial of 290 premenopausal women with unexplained fatigue and low iron who received one 1000 mg IV dose of ferric carboxymaltose (FCM) or saline placebo. By Day 56, more women given FCM had reduced fatigue and larger improvements in some quality-of-life and cognitive scores, and…
